Cargando…

Favourable response of serum prostate-specific antigen to conjugated oestrogen in castrate-resistant prostate cancer in Jamaica

Conjugated oestrogen is one of the more affordable secondary hormonal options available for castrate-resistant prostate cancer (CRPC) in Jamaica. The present study was conducted to examine the disease response in Jamaican men with CRPC treated with conjugated oestrogen. This study retrospectively re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Condappa, Andrew, Gossell-Williams, Maxine, Aiken, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2018
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931810/ https://www.ncbi.nlm.nih.gov/pubmed/29743949 http://dx.doi.org/10.3332/ecancer.2018.829

Ejemplares similares

Evaluation of Plasma Circulating Cell Free DNA Concentration and Integrity in Patients with Prostate Cancer in Jamaica: A Preliminary Study
por: Condappa, Andrew, et al.
Publicado: (2020)

The PharmWatch programme: challenges to engaging the community pharmacists in Jamaica
por: Gossell-Williams, Maxine, et al.
Publicado: (2008)

Current state of prostate cancer treatment in Jamaica
por: Morrison, Belinda F, et al.
Publicado: (2014)

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Trends in the utilization of nuclear medicine technology in Jamaica: Audit of a private facility
por: Kennedy-Dixon, Tracia-Gay, et al.
Publicado: (2020)

Prostate Cancer Screening in Jamaica: Results of the Largest National Screening Clinic
por: Morrison, Belinda F., et al.
Publicado: (2016)

Chikungunya Virus Infection and Acute Elevation of Serum Prostate-Specific Antigen
por: Aiken, William Derval, et al.
Publicado: (2015)

The prevalence of major potential drug-drug interactions at a University health centre pharmacy in Jamaica
por: Kennedy-Dixon, Tracia-Gay, et al.
Publicado: (2015)

Oestrogens and oestrogen receptors in prostate cancer
por: Kowalska, Karolina, et al.
Publicado: (2016)

Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica
por: Mckenzie, Jodi-Ann, et al.
Publicado: (2018)

Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer
por: Cameron, Sarina, et al.
Publicado: (2023)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis in an androgen-sensitive rat prostatic adenocarcinoma.
por: Westin, P., et al.
Publicado: (1995)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
por: Pascoe, Abigail C, et al.
Publicado: (2012)

IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute
por: Katongole, Paul, et al.
Publicado: (2021)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2021)

Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration
por: Sutcliffe, S, et al.
Publicado: (2011)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
por: Chen, Jiaxian, et al.
Publicado: (2022)

Consequences of Different Corticosteroids on Serum Potassium and Prostate-Specific Antigen in Patients Receiving Abiraterone for Castration-Resistant Prostate Cancer: A Retrospective Observational Study
por: Tatsuzawa, Masaomi, et al.
Publicado: (2017)

Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics
por: Brady-Nicholls, Renee, et al.
Publicado: (2021)

Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice
por: Zhao, Liang-Yun, et al.
Publicado: (2012)

Brief report: Impact of healthcare quality on prostate specific antigen screening for the early detection of prostate cancer
por: Rezaee, Michael E., et al.
Publicado: (2019)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
por: Kessel, Katharina, et al.
Publicado: (2021)

Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
por: Song, Geehyun, et al.
Publicado: (2013)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
por: Schiff, Joshua P., et al.
Publicado: (2019)

Phage display screening identifies a prostate specific antigen (PSA)(–/lo) prostate cancer cell specific peptide to retard castration resistance of prostate cancer
por: Sui, Yi, et al.
Publicado: (2021)

Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Han, Sangwon, et al.
Publicado: (2021)

Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma
por: Yin, Ming, et al.
Publicado: (2007)

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial
por: Määttänen, L, et al.
Publicado: (2007)

Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer
por: Keresztes, Dávid, et al.
Publicado: (2021)

Prostate cancer educational intervention among men in Western Jamaica
por: Capanna, Christian, et al.
Publicado: (2015)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer
por: Hiroshige, Tasuku, et al.
Publicado: (2018)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
por: Nagaya, Naoya, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
por: Perera, Mahasha P.J., et al.
Publicado: (2022)

Toward a Prostate Specific Antigen-Based Prostate Cancer Diagnostic Assay: Preparation of Keyhole Limpet Hemocyanin -Conjugated Normal and Transformed Prostate Specific Antigen Fragments
por: Dudkin, Vadim Y., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_hltq176a3atcdf3glp3f705nk3